Logo image of BLCM

BELLICUM PHARMACEUTICALS INC (BLCM) Stock Fundamental Analysis

NASDAQ:BLCM - Nasdaq - US0794814048 - Common Stock - Currency: USD

0.622  -0.07 (-9.72%)

After market: 0.6288 +0.01 (+1.09%)

Fundamental Rating

3

Overall BLCM gets a fundamental rating of 3 out of 10. We evaluated BLCM against 568 industry peers in the Biotechnology industry. The financial health of BLCM is average, but there are quite some concerns on its profitability. BLCM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BLCM has reported negative net income.
In the past year BLCM has reported a negative cash flow from operations.
In the past 5 years BLCM always reported negative net income.
In the past 5 years BLCM always reported negative operating cash flow.
BLCM Yearly Net Income VS EBIT VS OCF VS FCFBLCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for BLCM are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLCM Yearly ROA, ROE, ROICBLCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 1K 1.5K 2K

1.3 Margins

BLCM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLCM Yearly Profit, Operating, Gross MarginsBLCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

BLCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLCM has been increased compared to 1 year ago.
There is no outstanding debt for BLCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BLCM Yearly Shares OutstandingBLCM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M
BLCM Yearly Total Debt VS Total AssetsBLCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -51.30, we must say that BLCM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BLCM (-51.30) is worse than 92.16% of its industry peers.
BLCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -51.3
ROIC/WACCN/A
WACC8.6%
BLCM Yearly LT Debt VS Equity VS FCFBLCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.65 indicates that BLCM has no problem at all paying its short term obligations.
With a Current ratio value of 3.65, BLCM is not doing good in the industry: 61.60% of the companies in the same industry are doing better.
BLCM has a Quick Ratio of 3.65. This indicates that BLCM is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BLCM (3.65) is worse than 60.64% of its industry peers.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.65
BLCM Yearly Current Assets VS Current LiabilitesBLCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

BLCM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -183.10%.
The Revenue for BLCM has decreased by -75.68% in the past year. This is quite bad
The Revenue has been growing by 51.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-183.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y-40.55%
Revenue growth 5Y51.17%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BLCM will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.54% on average per year.
Based on estimates for the next years, BLCM will show a very strong growth in Revenue. The Revenue will grow by 187.52% on average per year.
EPS Next Y38.37%
EPS Next 2Y26.89%
EPS Next 3Y19.89%
EPS Next 5Y13.54%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y187.52%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLCM Yearly Revenue VS EstimatesBLCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2027 50M 100M 150M 200M
BLCM Yearly EPS VS EstimatesBLCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BLCM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLCM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLCM Price Earnings VS Forward Price EarningsBLCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLCM Per share dataBLCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as BLCM's earnings are expected to grow with 19.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.89%
EPS Next 3Y19.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLCM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELLICUM PHARMACEUTICALS INC

NASDAQ:BLCM (6/1/2023, 8:00:02 PM)

After market: 0.6288 +0.01 (+1.09%)

0.622

-0.07 (-9.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-11 2023-05-11/amc
Earnings (Next)08-09 2023-08-09
Inst Owners0.06%
Inst Owner Change0%
Ins Owners53.88%
Ins Owner Change0%
Market Cap5.91M
Analysts43.33
Price Target5.1 (719.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.92%
Min EPS beat(2)25.03%
Max EPS beat(2)78.81%
EPS beat(4)4
Avg EPS beat(4)62.53%
Min EPS beat(4)25.03%
Max EPS beat(4)81.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-222.22%
EPS NQ rev (3m)-45%
EPS NY rev (1m)0%
EPS NY rev (3m)46.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.92
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-2.72
FCFYN/A
OCF(TTM)-2.72
OCFYN/A
SpS0.16
BVpS1.32
TBVpS1.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 211.11%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.65
Altman-Z -51.3
F-Score1
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)80.14%
Cap/Depr(5y)54.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-183.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
EPS Next Y38.37%
EPS Next 2Y26.89%
EPS Next 3Y19.89%
EPS Next 5Y13.54%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y-40.55%
Revenue growth 5Y51.17%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y187.52%
EBIT growth 1Y-35.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.93%
OCF growth 3YN/A
OCF growth 5YN/A